Loading clinical trials...

COMPLETEDPHASE2

Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy

Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study

NCT00694863•Radboud University Medical Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether treatment with long-acting synthetic adrenocorticotropic hormone is in the treatment of patients with idiopathic membranous nephropathy and high for renal failure.

Eligibility

Age

18 - 95 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Biopsy-proven idiopathic membranous nephropathy.
•Nephrotic syndrome: proteinuria \> 3.5 g/day and serum albumine \< 30 g/l
•Normal or mildly impaired renal function (eGFR \> 60 ml/min, MDRD formula)
•High risk for renal failure: beta-2-microglobulin excretion \> 500 ng/min
•Relative contra-indication for cyclophosphamide treatment:
•* fertility and wish for (future) family expanding
•* high age ( \> 60 years)
•* former cyclophosphamide treatment
•* intolerance to cyclophosphamide

Exclusion Criteria

•Clinical,biochemical or histological signs of any underlying systemic disease
•Any infectious disease (including latent tuberculosis and/or latent amoebiasis)
•Active gastric or duodenal ulcers
•Pregnancy, lactation, inadequate contraceptives
•Clinical signs of renal vein thrombosis
•Asthma and /or any allergic conditions or hypersensitivity reactions
•Allergic reaction to synthetic ACTH in the past

Locations (1)

Radboud University

Nijmegen, Netherlands

Key Dates

Start Date

July 1, 2008

Primary Completion Date

December 1, 2010

Completion Date

December 1, 2012

Last Updated

January 7, 2013

Enrollment

ACTUAL participants

Conditions

Idiopathic Membranous Nephropathy

Interventions

tetracosactide hexacetaat

DRUG

Personalized Medicine for Membranous Nephropathy

NCT03804359

Idiopathic Membranous Nephropathy

View study

UNKNOWNNA

Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy

NCT05782933

Idiopathic Membranous Nephropathy

View study

UNKNOWNNA

Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy

NCT03864250

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 7, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy

Inclusion Criteria

Exclusion Criteria

Personalized Medicine for Membranous Nephropathy

Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy

Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy

MEmbranous Nephropathy Trial Of Rituximab

Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy

Aliskiren in Patients With Idiopathic Membranous Nephropathy